Zobrazeno 1 - 10
of 109
pro vyhledávání: '"G12V"'
Publikováno v:
Biomolecules & Biomedicine (2024)
Kirsten Rat Sarcoma viral oncogene homolog (KRAS) is one of the most frequent oncogenes. However, there are limited treatment options due to its intracellular expression. To address this, we developed a novel bispecific T-cell engager (BiTE) antibody
Externí odkaz:
https://doaj.org/article/b5dde72abb644e3284a0c7d7d6422d16
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
BackgroundAcute myeloid leukemia (AML) is a malignant disease originating from myeloid hematopoietic stem cells. Recent studies have shown that certain gene mutations promote tumor cell survival and affect the prognosis of patients by affecting metab
Externí odkaz:
https://doaj.org/article/2eba11131d0b47ab9b76ae1ac479afb5
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Qi Ai, Fanlu Li, Siyi Zou, Zehui Zhang, Yangbing Jin, Lingxi Jiang, Hao Chen, Xiaxing Deng, Chenghong Peng, Nan Mou, Chenlei Wen, Baiyong Shen, Qian Zhan
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
KRAS mutation is a significant driving factor of tumor, and KRASG12V mutation has the highest incidence in solid tumors such as pancreatic cancer and colorectal cancer. Thus, KRASG12V neoantigen-specific TCR-engineered T cells could be a promising ca
Externí odkaz:
https://doaj.org/article/b4dde58416184cff8635d96bf9bbd609
Autor:
Daniele Lavacchi, Sara Fancelli, Giandomenico Roviello, Francesca Castiglione, Enrico Caliman, Gemma Rossi, Jacopo Venturini, Elisa Pellegrini, Marco Brugia, Agnese Vannini, Caterina Bartoli, Fabio Cianchi, Serena Pillozzi, Lorenzo Antonuzzo
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
BackgroundAbout half of metastatic colorectal cancers (CRCs) harbor Rat Sarcoma (RAS) activating mutations as oncogenic driver, but the prognostic role of RAS mutations is not fully elucidated. Interestingly, specific hotspot mutations have been iden
Externí odkaz:
https://doaj.org/article/51c2fe7fe70a4130b91e5366f00b6537
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Liyuan Gao, Weizhang Shen
Publikováno v:
Frontiers in Genetics, Vol 13 (2022)
Lung cancer is one of the most common causes of cancer-related deaths, and non-small-cell lung cancer (NSCLC) accounts for approximately 85% of all lung cancer cases. Kirsten rat sarcoma virus (KRAS), one of the three subtypes of the RAS family, is t
Externí odkaz:
https://doaj.org/article/3a2f1f0020d249a7826caa0a9fb2ebbb
Autor:
Etsuko Miyamoto-Sato, Satoshi Imanishi, Lijuan Huang, Shoko Itakura, Yoichi Iwasaki, Masamichi Ishizaka
Publikováno v:
Molecules, Vol 28, Iss 14, p 5600 (2023)
“Undruggable” targets such as KRAS are particularly challenging in the development of drugs. We devised a novel chemical knockdown strategy, CANDDY (Chemical knockdown with Affinity aNd Degradation DYnamics) technology, which promotes protein deg
Externí odkaz:
https://doaj.org/article/c5fc44b190e545cb960106366a050147
Autor:
Ying Shen, Xiaoyue Wei, Shijie Jin, Yue Wu, Wenbin Zhao, Yingchun Xu, Liqiang Pan, Zhan Zhou, Shuqing Chen
Publikováno v:
Asian Journal of Pharmaceutical Sciences, Vol 15, Iss 6, Pp 777-785 (2020)
Limited clinical application of antibody-drug conjugates (ADCs) targeting tumor associated antigens (TAAs) is usually caused by on-target off-tumor side effect. Tumor-specific mutant antigens (TSMAs) only expressed in tumor cells which are ideal targ
Externí odkaz:
https://doaj.org/article/4407510eb25f41749d040124d5b6db87